Twist Bioscience CorporationTWSTNASDAQ

|||

Overview Charts News Fundamentals Key Metrics TTM Financials Earnings Growth Rating Analysts Institutional Peers Historical

Latest News

businesswire.com

Twist Bioscience Announces Fiscal 2026 First Quarter Financial Results

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today announced financial results and business highlights for the first quarter fiscal 2026 ended December 31, 2025. Visit the Events and Presentations page of the Investor Relations section under the “Company” tab at www.twistbioscience.com to view the detailed fiscal first quarter 2026 earnings report and the investor presentation, or click https://investors.t.

investorplace.com

The Genesis Mission Has a 270-Day Timeline – And You’re Already Late

The government is taking equity stakes in American companies. Here are the next Genesis Mission stocks to buy before the capital hits.

zacks.com

Will Twist Bioscience (TWST) Report Negative Earnings Next Week? What You Should Know

Twist Bioscience (TWST) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

defenseworld.net

Twist Bioscience (NASDAQ:TWST) CFO Sells $120,000.00 in Stock

Twist Bioscience Corporation (NASDAQ: TWST - Get Free Report) CFO Adam Laponis sold 3,000 shares of the business's stock in a transaction dated Tuesday, January 13th. The shares were sold at an average price of $40.00, for a total value of $120,000.00. Following the completion of the transaction, the chief financial officer directly owned 137,031 shares

defenseworld.net

Twist Bioscience Corporation (NASDAQ:TWST) Given Average Rating of “Moderate Buy” by Analysts

Shares of Twist Bioscience Corporation (NASDAQ: TWST - Get Free Report) have received a consensus rating of "Moderate Buy" from the eleven brokerages that are covering the stock, Marketbeat.com reports. Two research analysts have rated the stock with a sell recommendation and nine have issued a buy recommendation on the company. The average twelve-month price objective

seekingalpha.com

Twist Bioscience Corporation (TWST) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

businesswire.com

Twist Bioscience Announces Preliminary First Quarter Fiscal 2026 Revenue

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today announced preliminary, unaudited revenue for the first quarter of fiscal 2026 ended December 31, 2025. Visit the Events and Presentations page of the Investor Relations section under the “Company” tab at www.twistbioscience.com to view the fiscal 2026 first quarter preliminary, unaudited revenue, or click https://investors.twistbioscience.com/events-and-pr.

gurufocus.com

ARK Invest Boosts Gene-Editing Bets While Cutting Consumer Tech Exposure

Cathie Wood's ARK Invest is entering 2026 with a noticeably sharper bet on early-stage biotechnology, while selectively reducing exposure to consumer technology

gurufocus.com

Cathie Wood Doubles Down on Biotech as 2025 Ends, Offloads Rocket Lab

Cathie Wood's ARK Invest made a series of end-of-year portfolio adjustments on the second final trading day of 2025, tilting further toward biotechnology while

gurufocus.com

TSLA: Cathie Wood Dumps $30 Million Worth Tesla Stock

Cathie Wood's Ark Invest increased stakes in gene-editing and autonomous mobility companies while trimming holdings in Tesla (TSLA) and Rocket Lab (RKLB).Sellin

investorplace.com

The Genesis Mission Has a 270-Day Timeline – And You’re Already Late

The government is taking equity stakes in American companies. Here are the next Genesis Mission stocks to buy before the capital hits.

businesswire.com

Twist Bioscience to Present at J.P. Morgan 2026 Healthcare Conference

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today announced that Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience, will present at the J.P. Morgan 2026 Healthcare Conference on Monday, January 12, 2026 at 2:15 pm Pacific Time in San Francisco. The presentation will be webcast live and can be accessed by visiting the “Investor Calendar” page of the investor relations section of the company'.

businesswire.com

Halper Sadeh LLC Encourages Twist Bioscience Corporation Shareholders to Contact the Firm to Discuss Their Rights

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of Twist Bioscience Corporation (NASDAQ: TWST) breached their fiduciary duties to shareholders. If you currently own Twist stock and are a long-term shareholder, you may be able to seek corporate governance reforms, the return of funds back to the company, a court-approved financial incentive award, or other relief and benefits. Please click here to learn more about.

businesswire.com

Twist Bioscience Launches New Plasmid Preps to Enable Nucleic Acid Therapeutics Research

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today launched research-grade Plasmid DNA Preps designed to support the advancement of pharmaceutical and biotech customers' pre-clinical studies. “Our new plasmid preps combine the quality and consistency needed for preclinical research with the speed and cost efficiency customers have come to expect from Twist,” said Emily M. Leproust, CEO and co-founder of Tw.

globenewswire.com

Kuehn Law Encourages Investors of Twist Bioscience Corporation to Contact Law Firm

NEW YORK, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Twist Bioscience Corporation (NASDAQ: TWST) breached their fiduciary duties to shareholders.

seekingalpha.com

Twist Bioscience Is Bent, Not Broken: Near-Term Strain, Long-Term Strength

Twist's revenue growth continues to moderate due to macro headwinds and temporary challenges in the NGS business. The Biopharma segment is reaccelerating, though, driven by AI-enabled drug discovery customers, and NGS growth will rebound in FY27, driven by MRD customers. Twist's margins also continue to improve, and the company should start to generate positive cash flows within the next 1-2 years.

forbes.com

Can Twist Bioscience Drop More?

Twist Bioscience (TWST) stock has decreased by 10.1% in one day. The recent downturn signifies renewed worries regarding wider-than-anticipated losses and ambiguous profitability guidance, but significant drops like this often prompt a more challenging question: is this weakness merely temporary, or does it indicate more profound issues in the narrative?

defenseworld.net

Twist Bioscience (NASDAQ:TWST) Hits New 12-Month Low Following Weak Earnings

Twist Bioscience Corporation (NASDAQ: TWST - Get Free Report)'s share price reached a new 52-week low during trading on Friday following a weaker than expected earnings announcement. The company traded as low as $23.30 and last traded at $26.2110, with a volume of 2152422 shares. The stock had previously closed at $29.90. The company reported ($0.45)

seekingalpha.com

Twist Bioscience Corporation (TWST) Q4 2025 Earnings Call Transcript

benzinga.com

Twist Bioscience Eyes Profit Turnaround In 2026 After Narrowing Losses

Twist Bioscience Corporation (NASDAQ: TWST) on Friday posted mixed fourth-quarter results, reporting a loss of 45 cents per share, slightly wider than the consensus estimate of a 43-cent loss.

Loading news...

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance